{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:02:12Z","timestamp":1777917732310,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2001,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatic arterial infusion chemotherapy is a promising approach in liver metastases from colorectal cancer, but chemical hepatitis, biliary sclerosis, arterial thrombosis and right upper quadrant pain are limiting factors. Irinotecan (CPT-11) is an active drug in colorectal cancer. We planned a short hepatic arterial infusion of CPT-11 to describe the toxicity, to determine the dose-limiting toxicity, and to define the doses of CPT-11 to be recommended for phase II studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Fourteen patients with a median liver substitution of 30% (10-60%) were enrolled. All patients received hepatic arterial infusion chemotherapy with CPT-11 on an outpatient basis every 3 weeks as a short, 30-min infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At 240 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , 2 of 4 patients experienced grade 4 diarrhea and neutropenia, and 3 of them also reported grade 4 abdominal pain of the right upper quadrant. The maximum tolerated dose was reached at 240 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . The recommended doses of CPT-11 for phase II studies is 200 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , given every 3 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CPT-11 presents a low hepatic toxic profile and could be considered a new active drug, suitable for hepatic arterial infusion in liver metastases from colorectal cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/030089160108700606","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T12:37:26Z","timestamp":1523882246000},"page":"388-390","source":"Crossref","is-referenced-by-count":15,"title":["Irinotecan Hepatic Arterial Infusion Chemotherapy for Hepatic Metastases from Colorectal Cancer: Results of a Phase I Clinical Study"],"prefix":"10.1177","volume":"87","author":[{"given":"Giammaria","family":"Fiorentini","sequence":"first","affiliation":[{"name":"Department of Oncology and Hematology, Ravenna;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Ricci","family":"Lucchi","sequence":"additional","affiliation":[{"name":"Pharmacology Unit, City Hospital \u201cS Maria delle Croci\u201d, Ravenna;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Giovanis","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Ravenna;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Cantore","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, City Hospital \u201cC Poma\u201d, Mantova;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Guadagni","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of L'Aquila, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Papiani","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, Ravenna;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2001,11,1]]},"reference":[{"key":"bibr1-030089160108700606","doi-asserted-by":"publisher","DOI":"10.1016\/0305-7372(94)90011-6"},{"key":"bibr2-030089160108700606","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.8.2910"},{"key":"bibr3-030089160108700606","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)02309-5"},{"key":"bibr4-030089160108700606","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051077"},{"key":"bibr5-030089160108700606","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059109"},{"key":"bibr6-030089160108700606","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689205"},{"key":"bibr7-030089160108700606","first-page":"3723","volume":"54","author":"Gupta E.","year":"1994","journal-title":"Cancer Res"},{"key":"bibr8-030089160108700606","first-page":"1342","volume":"6","author":"Van Groeningen C.J.","year":"2000","journal-title":"Clin Cancer Res"},{"key":"bibr9-030089160108700606","volume":"19","author":"Farabos C.","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"bibr10-030089160108700606","author":"Kerr J.Z.","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"bibr11-030089160108700606","volume":"40","author":"Guichard S.","year":"1999","journal-title":"Proc Am Ass Cancer Res"},{"key":"bibr12-030089160108700606","volume":"16","author":"Van Groeningen C.J.","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"bibr13-030089160108700606","first-page":"600","volume":"39","author":"Van der Vijgh W.J.F.","year":"1998","journal-title":"Proc Am Assoc Cancer Res"},{"key":"bibr14-030089160108700606","doi-asserted-by":"publisher","DOI":"10.1007\/BF02780523"},{"key":"bibr15-030089160108700606","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.684"},{"key":"bibr16-030089160108700606","first-page":"469","volume":"4","author":"Longo G.S.A.","year":"1998","journal-title":"Clin Cancer Res"},{"key":"bibr17-030089160108700606","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00222-1"}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089160108700606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/030089160108700606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:21:38Z","timestamp":1777659698000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/030089160108700606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["10.1177\/030089160108700606"],"URL":"https:\/\/doi.org\/10.1177\/030089160108700606","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,11]]}}}